Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 24 of 24 matching drugs for SRMS — including drugs targeting any of its 7 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
dasatinib SRMS Direct yes 0
vandetanib SRMS Direct yes 0
adagrasib KRAS SSL via KRAS yes 2
sotorasib KRAS SSL via KRAS yes 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SRC SSL via SRC 3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SRC SSL via SRC 2
nintedanib SRC SSL via SRC 2
nintedanib, pembrolizumab SRC SSL via SRC 2
afatinib, dasatinib, palbociclib, everolimus, olaparib SRC SSL via SRC 1
bevacizumab, dasatinib, placebo SRC SSL via SRC 1
bosutinib SRC SSL via SRC yes 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab SRC SSL via SRC 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride SRC SSL via SRC 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method SRC SSL via SRC 1
dasatinib, laboratory biomarker analysis, physiologic testing SRC SSL via SRC 1
dasatinib, mfolfox6 SRC SSL via SRC 1
dasatinib, pharmacological study SRC SSL via SRC 1
dasatinib, temozolomide, placebo, radiation therapy SRC SSL via SRC 1
ponatinib SRC SSL via SRC 1
dasatinib BLK SSL via BLK yes 0
dasatinib SRC SSL via SRC yes 0
tirbanibulin SRC SSL via SRC yes 0
vandetanib BLK SSL via BLK yes 0
vandetanib SRC SSL via SRC yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.